The type 1 insulin‐like growth factor receptor is over‐expressed in bladder cancer

To analyse bladder cancer biopsies and investigate the pattern of expression of the type 1 insulin‐like growth factor receptor (IGF1R), a receptor tyrosine kinase that mediates tumour cell proliferation, motility and protection from apoptosis.

[1]  R. Poulsom,et al.  Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. , 2002, Cancer research.

[2]  D. Hanahan,et al.  Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. , 2002, Cancer cell.

[3]  Arnab Chakravarti,et al.  Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.

[4]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[5]  P. Abel.  Prognostic indices in transitional cell carcinoma of the bladder. , 1988, British journal of urology.

[6]  I. Ellis,et al.  Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. , 2005, Endocrine-related cancer.

[7]  N. James,et al.  Molecular pathways in bladder cancer: Part 2 , 2005, BJU international.

[8]  E. Bohula,et al.  Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment , 2003, Anti-Cancer Drugs.

[9]  D. Leroith,et al.  PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.

[10]  P. Glazer,et al.  Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. , 1997, Cancer research.

[11]  H. Werner,et al.  Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. , 2000, Molecular genetics and metabolism.

[12]  M. Moore,et al.  Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Abel,et al.  Should pT1 transitional cell cancers of the bladder still be classified as superficial? , 1988, British journal of urology.

[14]  T. Wilt,et al.  A meta-analysis of randomised trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice? , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[15]  Muhammad Sohail,et al.  The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. , 2007, Biochemical and biophysical research communications.

[16]  K. Garber.  IGF-1: old growth factor shines as new drug target. , 2005, Journal of the National Cancer Institute.

[17]  S. Groshen,et al.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. , 1993, The American journal of pathology.

[18]  M. May,et al.  Survival Rates after Radical Cystectomy according to Tumor Stage of Bladder Carcinoma at First Presentation , 2004, Urologia Internationalis.

[19]  A. Kamat,et al.  Treatment of muscle-invasive bladder cancer: progress and new challenges , 2004, Expert review of anticancer therapy.

[20]  H. Werner,et al.  The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma , 2007, Oncogene.

[21]  Leaf Huang,et al.  Recent advances in intravesical drug/gene delivery. , 2006, Molecular pharmaceutics.

[22]  D. Coppola,et al.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.

[23]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Neal,et al.  Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer , 2004, Clinical Cancer Research.

[25]  P. Sluss,et al.  Characterization of insulin-like growth factor I binding sites in human bladder cancer cell lines , 2004, Urological Research.

[26]  J. Herman,et al.  Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.

[27]  Domenico Coppola,et al.  Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. , 2003, Human pathology.

[28]  H. Werner,et al.  Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  N. Anderson,et al.  The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[30]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[31]  A. Harris,et al.  Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. , 1989, Cancer research.

[32]  M. Pollak,et al.  Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells , 2005, Breast Cancer Research.

[33]  C. Dinney,et al.  Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. , 2003, Critical reviews in oncology/hematology.

[34]  J. Lunec,et al.  Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2 , 2004, British Journal of Cancer.

[35]  M. Bennett,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS , 1985, The Lancet.

[36]  M. Rubini,et al.  The IGF-I receptor in cell growth, transformation and apoptosis. , 1997, Biochimica et biophysica acta.

[37]  A B West,et al.  Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. , 1986, The Journal of urology.

[38]  D. Bajorin,et al.  Overview of bladder cancer trials in the Cancer and Leukemia Group B , 2003, Cancer.

[39]  C. Cordon-Cardo,et al.  Genetic and Immunophenotype Analyses of TP53 in Bladder Cancer: TP53 Alterations Are Associated with Tumor Progression , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[40]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[41]  N. James,et al.  Molecular pathways in bladder cancer: Part 1 , 2005, BJU international.